The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells

Youngjoo Byun, Jongho Park, Soo Hyun Hong, Mi Hwa Han, Suzie Park, Hyo Il Jung, Minsoo Noh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Adiponectin production during adipocyte differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs) can be used to evaluate the pharmacological activity of anti-diabetic drugs to improve insulin sensitivity. Monoamine oxidase (MAO) inhibitors such as phenelzine and pargyline inhibit adipogenesis in murine pre-adipocytes. In this study, however, we found that selective MAO-A inhibitors, moclobemide and Ro41-1049, and a selective MAO-B inhibitor, selegiline, promoted adiponectin production during adipocyte differentiation in hBM-MSCs, which suggested the anti-diabetic potential of these drugs. In contrast, non-selective MAO inhibitors, phenelzine and tranylcypromine, inhibited adipocyte differentiation of hBM-MSCs. Concomitant treatments of MAO-A and MAO-B selective inhibitors did not change the stimulatory effect on adiponectin production in hBM-MSCs. Taken together, the opposite effects of isotype-selective MAO inhibitors on adiponectin production during adipogenesis in hBM-MSCs may not be directly associated with the inhibitory effects of MAO, suggested that the structure of MAO inhibitors may contain a novel anti-diabetic pharmacophore.

Original languageEnglish
Pages (from-to)3273-3276
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume23
Issue number11
DOIs
Publication statusPublished - 2013 Jun 1

Fingerprint

Adipogenesis
Monoamine Oxidase Inhibitors
Monoamine Oxidase
Stem cells
Mesenchymal Stromal Cells
Adiponectin
Bone
Bone Marrow
Adipocytes
Phenelzine
Moclobemide
Tranylcypromine
Pargyline
Selegiline
Pharmaceutical Preparations
Insulin Resistance
Insulin
Pharmacology

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Byun, Youngjoo ; Park, Jongho ; Hong, Soo Hyun ; Han, Mi Hwa ; Park, Suzie ; Jung, Hyo Il ; Noh, Minsoo. / The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells. In: Bioorganic and Medicinal Chemistry Letters. 2013 ; Vol. 23, No. 11. pp. 3273-3276.
@article{57ceba16493d4e7b8dedff37e06a407c,
title = "The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells",
abstract = "Adiponectin production during adipocyte differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs) can be used to evaluate the pharmacological activity of anti-diabetic drugs to improve insulin sensitivity. Monoamine oxidase (MAO) inhibitors such as phenelzine and pargyline inhibit adipogenesis in murine pre-adipocytes. In this study, however, we found that selective MAO-A inhibitors, moclobemide and Ro41-1049, and a selective MAO-B inhibitor, selegiline, promoted adiponectin production during adipocyte differentiation in hBM-MSCs, which suggested the anti-diabetic potential of these drugs. In contrast, non-selective MAO inhibitors, phenelzine and tranylcypromine, inhibited adipocyte differentiation of hBM-MSCs. Concomitant treatments of MAO-A and MAO-B selective inhibitors did not change the stimulatory effect on adiponectin production in hBM-MSCs. Taken together, the opposite effects of isotype-selective MAO inhibitors on adiponectin production during adipogenesis in hBM-MSCs may not be directly associated with the inhibitory effects of MAO, suggested that the structure of MAO inhibitors may contain a novel anti-diabetic pharmacophore.",
author = "Youngjoo Byun and Jongho Park and Hong, {Soo Hyun} and Han, {Mi Hwa} and Suzie Park and Jung, {Hyo Il} and Minsoo Noh",
year = "2013",
month = "6",
day = "1",
doi = "10.1016/j.bmcl.2013.03.117",
language = "English",
volume = "23",
pages = "3273--3276",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "11",

}

The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells. / Byun, Youngjoo; Park, Jongho; Hong, Soo Hyun; Han, Mi Hwa; Park, Suzie; Jung, Hyo Il; Noh, Minsoo.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 23, No. 11, 01.06.2013, p. 3273-3276.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells

AU - Byun, Youngjoo

AU - Park, Jongho

AU - Hong, Soo Hyun

AU - Han, Mi Hwa

AU - Park, Suzie

AU - Jung, Hyo Il

AU - Noh, Minsoo

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Adiponectin production during adipocyte differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs) can be used to evaluate the pharmacological activity of anti-diabetic drugs to improve insulin sensitivity. Monoamine oxidase (MAO) inhibitors such as phenelzine and pargyline inhibit adipogenesis in murine pre-adipocytes. In this study, however, we found that selective MAO-A inhibitors, moclobemide and Ro41-1049, and a selective MAO-B inhibitor, selegiline, promoted adiponectin production during adipocyte differentiation in hBM-MSCs, which suggested the anti-diabetic potential of these drugs. In contrast, non-selective MAO inhibitors, phenelzine and tranylcypromine, inhibited adipocyte differentiation of hBM-MSCs. Concomitant treatments of MAO-A and MAO-B selective inhibitors did not change the stimulatory effect on adiponectin production in hBM-MSCs. Taken together, the opposite effects of isotype-selective MAO inhibitors on adiponectin production during adipogenesis in hBM-MSCs may not be directly associated with the inhibitory effects of MAO, suggested that the structure of MAO inhibitors may contain a novel anti-diabetic pharmacophore.

AB - Adiponectin production during adipocyte differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs) can be used to evaluate the pharmacological activity of anti-diabetic drugs to improve insulin sensitivity. Monoamine oxidase (MAO) inhibitors such as phenelzine and pargyline inhibit adipogenesis in murine pre-adipocytes. In this study, however, we found that selective MAO-A inhibitors, moclobemide and Ro41-1049, and a selective MAO-B inhibitor, selegiline, promoted adiponectin production during adipocyte differentiation in hBM-MSCs, which suggested the anti-diabetic potential of these drugs. In contrast, non-selective MAO inhibitors, phenelzine and tranylcypromine, inhibited adipocyte differentiation of hBM-MSCs. Concomitant treatments of MAO-A and MAO-B selective inhibitors did not change the stimulatory effect on adiponectin production in hBM-MSCs. Taken together, the opposite effects of isotype-selective MAO inhibitors on adiponectin production during adipogenesis in hBM-MSCs may not be directly associated with the inhibitory effects of MAO, suggested that the structure of MAO inhibitors may contain a novel anti-diabetic pharmacophore.

UR - http://www.scopus.com/inward/record.url?scp=84877580770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877580770&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2013.03.117

DO - 10.1016/j.bmcl.2013.03.117

M3 - Article

C2 - 23611731

AN - SCOPUS:84877580770

VL - 23

SP - 3273

EP - 3276

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 11

ER -